5-Day Repeated Intravenous Dose Toxicity Study of a New Camptothecin Anticancer Agent CKD-602 in Rats |
Kim, Jong-Choon
(College of Veterinary Medicine, Chonnam National University)
Shin, Dong-Ho (College of Veterinary Medicine, Chonnam National University) Kim, Sung-Ho (College of Veterinary Medicine, Chonnam National University) Bae, Chun-Sik (College of Veterinary Medicine, Chonnam National University) Kim, Joon-Kyum (Medicinal Research Center, Chong Kun Dang Co.) Cha, Shin-Woo (Korea Institute of Toxicology) Han, Jung-Hee (Korea Institute of Toxicology) Lee, Hyun-Sook (Korea Institute of Toxicology) Chung, Moon-Koo (Korea Institute of Toxicolog) |
1 | Bleiberg, H. and Rothenberg, M.L. (1996): CPT-11: From DNA topology to clinical activity, Semi. Oncol., 23, 1-50 |
2 | Hertzberg, R.P., Caranfa, M.J., Holden, K.G., Jakas, D.R., Gallagher, G., Mattern, M.R., Mong, S.M., Bartus, J.O., Johnson, R.K. and Kingsbury, W.D. (1989): Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity, J. Med. Chem., 32, 715-720 DOI PUBMED |
3 | Lee, J.H., Lee, J.M., Kim, J.K., Ahn, S.K., Lee, S.J., Kim, M.Y., Jew, S.S., Park, J.G. and Hong, C.I. (1998): Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)- camp-tothecin, CKD602, as a potent DNA topoisomerase I inhibitor, Arch. Pharm. Res., 21, 581-590. |
4 | Moertel, C.G., Schutt, A.J., Reitmeier, R.J. and Hahn, R.G. (1972): Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer, Can-cer Chemother. Rep., 56, 95-101 |
5 | Pizzolato, J.F. and Saltz, L.B. (2003): The camptothecins, Lancet, 361, 2235-2242 |
6 | Pratesi, G., Tortoreto, M., Corti, C., Giardini, R. and Zunino, F. (1995): Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts, Br. J. Cancer. 71, 525-528 |
7 | Kim, J.H., Lee, S.K., Lim, J.L., Shin, H.J. and Hong, C.l. (2002): Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characteriza-tion and hydrolytic equilibrium kinetics, Int. J. Pharm., 239, 207-211 |
8 | Kim, J.C., Kim, K.H. and Chung, M.K. (1999): Testicular cyto-toxicity of DA-125, a new anthracycline anticancer agent, in rats, Reprod. Toxicol., 13, 391-397 |
9 | Takimoto, C.H., Wright, J. and Arbuck, S.G. (1998): Clinical applications of the camptothecins, Biochim. Biophys. Acta, 1400, 107-119 |
10 | Kim, J.C., Kim, S.H., Shin, D.H., Ahn, T.H., Kim, H.C., Kim, Y.B., Jiang, C.Z., Han, J. and Chung, M.K. (2004): Effects of prenatal exposure to the environmental pollutant 2-bro-mopropane on embryo-fetal development in rats, Toxicol-ogy, 196, 77-86 |
11 | Dahut, W., Harolod, N., Takimototo, C., Allegra, C., Chen, A., Hamilton, J.M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, W. and Grem, J. (1996): Phase I and pharmacokinetic study of 9-aminocamptothecin given as a 72-hour infusion in adult cancer patients, J. Clin. Oncol., 14, 1236-1244 |
12 | Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T. and Block, J.B. (1970): Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880), Can-cer Chemother. Rep., 54, 461-470 |
13 | Slichenmyer, W.J. and Rowinsky, E.K. (1993): The current status of camptothecin analogues as antitumor agents, J. Natl. Cancer Inst., 85, 271-291 DOI PUBMED |
14 | Song, C.W., Hwang, H.S. and Han, S.S. (1990): Studies on the basic data of Ktc: SD rats with age, Korean J. Lab. Ani. Sci., 6, 33-43 |
15 | SAS Institute, Inc, (1997): SAS/STAT Software: Changes and Enhancements Through Release 6.12. SAS Institute, Cary, NC |
16 | Kolimannsberger, C., Mross, K., Jakob, A., Kanz, L. and Boke-myer, C. (1999): Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience, Oncology, 56, 1-12 |
17 | Kim, E.J., Lee, R.K., Suh, J.E., Han, S.S. and Kim, J.K. (2003a): Safety pharmacology of CKD-602, a novel anti-cancer agent, Arzneimittel Forschung, 53, 272-279 |
18 | Hashimoto, H., Chatterjee, S. and Berger, N.A. (1995): Muta-genic activity of topoisomerase I inhibitors, Clin. Cancer Res., 1, 369-376 |
19 | Lee, J.H., Lee, J.M., Lim, K.H., Kim, J.K., Ahn, S.K., Bang, Y.J., and Hong, C.1. (2000): Preclinical and phase I clini-cal studies with CKD-602, a novel camptothecin deriva-tive, Ann. N. Y. Acad. Sci., 922, 324-325 |
20 | Kim, J.C., Shin, D.H., Ahn, T.H., Kang, S.S., Song, S.W., Han, J., Kim, C.Y., Ha, C.S. and Chung, M.K. (2003b): 26-Week repeated oral dose toxicity study of the new qui-nolone antibacterial DW-116 in Sprague-Dawley rats, Food Chem. Toxicol., 41, 637-645 |
![]() |